Asian economies must adjust to Covid-19
Asian countries have kept tight restrictions, and are only slowly rolling out vaccines. Markets are subdued, but better times may be coming.

We’re in the third year of the pandemic and travel in Asia is still “heavily restricted”, says Chad de Guzman in Time. Most Asian countries have done an excellent job fighting the pandemic: South Korea has recorded 12 deaths per 100,000 people, compared to 259 per 100,000 in America. But the arrival of Omicron has triggered a return to 2020-style measures.
Japan has banned most foreigners from visiting. Hong Kong “which once boasted one of the world’s ten busiest airports… banned all flights from eight countries including the US and the UK” earlier this month. Yet as cases of Omicron spike across the region, “experts question whether continuing to stay closed to tourists, students and business travellers” is still “an effective strategy”.
Southeast Asia in recovery
Tight restrictions and slow vaccine rollouts have weighed on stocks. The MSCI Asia Pacific index underperformed European and American shares in 2021, finishing the year down 2.5%. Southeast Asian markets have been particularly dull. The regional MSCI Asean benchmark has been flat over the last three years, even as the wider emerging markets index delivered gains of 11% a year. Vietnam’s VNI, which soared 35% last year, has been the only bright spot as other markets lagged global averages.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Delta wreaked havoc last summer, says Trinh Nguyen of the Carnegie Endowment for International Peace. Lockdowns disrupted Malaysian semiconductor production and Vietnamese textile manufacturing. GDP in the latter country tumbled 6% year-on-year in the third quarter.
However, better times may be coming. Vaccination rates in most countries in the region (with the exception of Indonesia and the Philippines) are now comparable to those in the UK. Southeast Asia is also a potential winner from worsening US-China relations. Companies are diversifying their supply chains, which is bringing more inward investment. Trans-Pacific “jockeying for power” has “allowed Vietnam to escape the United States’ currency-manipulator list”.
Commodities, not tourism
“The nexus of Asia-Pacific economic growth is shifting to Southeast Asia amid maturing recoveries in northeast Asia,” says RBC Capital Markets. “The retreating pandemic and higher commodity prices have catalysed a brightening growth outlook for Malaysia and Indonesia”. The latter is a significant coal and oil exporter.
The outlook for tourism is less encouraging, says The Economist. The sector “accounted for over 12% of the region’s GDP before the pandemic”. In 2019, Chinese tourists “made up 12 million of Thailand’s 39 million international arrivals”, but Beijing’s zero-Covid policies mean few Chinese visitors are travelling overseas anymore. “In Cambodia the temples of Angkor Wat are eerily empty.”
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
Reeves warned against property tax shake-up – 3 ways it could backfire on first-time buyers
Rachel Reeves reportedly has her eye on high-end property taxes in the upcoming Budget, but there are concerns a shake-up could unintentionally hamper those trying to get on the housing ladder
-
Average Brits want to retire five years before they can – who has the widest retirement gap?
Brits are expecting to work for longer than ever but there are big disparities in the number of extra working years predicted. A small tweak could help close the gap
-
Pierre-Édouard Stérin wants to make France great again
Conservative billionaire Pierre-Édouard Stérin is seeking to lead a political and spiritual renaissance across the Channel. The planning looks meticulous
-
Global investors have overlooked the top innovators in emerging markets
Opinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Pinewood Technologies: a drive for growth
Pinewood Technologies’ platform is one of the best in the business. Investors should buy in
-
'EV maker Faraday Future will crash'
Faraday Future Intelligent Electric is failing dismally to live up to its name, says Matthew Partridge
-
Investors should cheer the coming nuclear summer
The US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
8 of the best houses for sale with follies
The best houses for sale with follies in the grounds – from a five-storey Victorian Gothic tower in Tonbridge, Kent, to a former mill in Oxfordshire with gardens that include a folly on an island in a lake
-
A tale of two Reits – why performance matters for valuation
AEW UK and Regional are two Reits that are valued very differently, despite a shared focus on properties outside London
-
Healthcare stocks look cheap, but tread carefully
Shares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?